BioWorld

Feb. 6, 2004

View Archived Issues

XenoPort's Prodrug Efforts Yield $37M Equity Round

Biogen Idec, Celltech Team Up On CD40 Ligand Drugs

Nuvelo Adds Dendreon's Heart Product To Thickening Pipeline

Correction

Anika Wins Orthovisc Approval After Long Development Road

Other News To Note

Renovis Prices $66M IPO; SGI, Exact Pull In Follow-On Funds

Renovis Inc. entered the public arena as the third biotech company to conduct an initial public offering this year, raising $66 million. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld Science

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld Asia

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...